News
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...
2h
Everyday Health on MSNFDA Approves a ‘Game-Changing’ Twice-a-Year HIV Prevention ShotThe new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
The U.S. Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
1d
India Today on MSNLenacapavir becomes first FDA-approved HIV preventive drug: All about itThe US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a ...
Gilead Sciences’ Yeztugo receives nod; the first and only US FDA-approved HIV prevention option offering 6 months of protection: Foster City, California Friday, June 20, 2025, 1 ...
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo from company Gilead Sciences, remained ...
Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...
1d
GlobalData on MSNGilead Sciences’ Yeztugo receives approval from US FDA for HIVThe US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a ...
A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results